Cardiac Markers Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019

Published : Dec-2019

No. of Pages : 130

order by fax Inquire before Buying request discount

Table of Contents
1.1 List of Tables 5
1.2 List of Figures 9
2 Introduction 10
2.1 Cardiac Markers Rapid Tests & Point of Care (POC) Overview 10
3 Products under Development 11
3.1 Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 11
3.2 Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Segment 12
3.3 Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Territory 13
3.4 Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path 14
3.5 Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date 15
4 Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products under Development by Companies 16
4.1 Cardiac Markers Rapid Tests & Point of Care (POC) Companies - Pipeline Products by Stage of Development 16
4.2 Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 19
5 Cardiac Markers Rapid Tests & Point of Care (POC) Companies and Product Overview 22
5.1 1Drop Diagnostics Company Overview 22
5.1.1 1Drop Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 22
5.2 Abbott Point of Care Inc Company Overview 23
5.2.1 Abbott Point of Care Inc Pipeline Products & Ongoing Clinical Trials Overview 23
5.3 Accel Diagnostics LLC Company Overview 24
5.3.1 Accel Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 24
5.4 Akers Biosciences Inc Company Overview 25
5.4.1 Akers Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 25
5.5 Akrivis Technologies LLC Company Overview 26
5.5.1 Akrivis Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 26
5.6 Alfa Wassermann Inc Company Overview 27
5.6.1 Alfa Wassermann Inc Pipeline Products & Ongoing Clinical Trials Overview 27
5.7 Angle Biosciences Inc Company Overview 29
5.7.1 Angle Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 29
5.8 Anteo Diagnostics Ltd Company Overview 30
5.8.1 Anteo Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 30
5.9 Atonomics A/S Company Overview 31
5.9.1 Atonomics A/S Pipeline Products & Ongoing Clinical Trials Overview 31
5.10 Axis-Shield Diagnostics Ltd Company Overview 33
5.10.1 Axis-Shield Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 33
5.11 BBB Technologies Inc Company Overview 34
5.11.1 BBB Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 34
5.12 Bio-AMD Inc Company Overview 35
5.12.1 Bio-AMD Inc Pipeline Products & Ongoing Clinical Trials Overview 35
5.13 BioMedomics Inc Company Overview 38
5.13.1 BioMedomics Inc Pipeline Products & Ongoing Clinical Trials Overview 38
5.14 BiOracle Ltd (Inactive) Company Overview 39
5.14.1 BiOracle Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 39
5.15 Biosensia Ltd Company Overview 40
5.15.1 Biosensia Ltd Pipeline Products & Ongoing Clinical Trials Overview 40
5.16 Biostealth, Inc. Company Overview 41
5.16.1 Biostealth, Inc. Pipeline Products & Ongoing Clinical Trials Overview 41
5.17 Biosurfit, SA Company Overview 42
5.17.1 Biosurfit, SA Pipeline Products & Ongoing Clinical Trials Overview 42
5.18 Brava Diagnostics Company Overview 43
5.18.1 Brava Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 43
5.19 Carclo Diagnostic Solutions Ltd Company Overview 44
5.19.1 Carclo Diagnostic Solutions Ltd Pipeline Products & Ongoing Clinical Trials Overview 44
5.20 CardioGenics Inc Company Overview 45
5.20.1 CardioGenics Inc Pipeline Products & Ongoing Clinical Trials Overview 45
5.21 Cordex Systems, LLC Company Overview 46
5.21.1 Cordex Systems, LLC Pipeline Products & Ongoing Clinical Trials Overview 46
5.22 Coris BioConcept Company Overview 47
5.22.1 Coris BioConcept Pipeline Products & Ongoing Clinical Trials Overview 47
5.23 Critical Diagnostics Company Overview 48
5.23.1 Critical Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 48
5.24 Diazyme Laboratories Inc Company Overview 49
5.24.1 Diazyme Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 49
5.25 DSC Technologies Inc Company Overview 50
5.25.1 DSC Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 50
5.26 Duke University Company Overview 51
5.26.1 Duke University Pipeline Products & Ongoing Clinical Trials Overview 51
5.27 Dynasil Corporation of America Company Overview 53
5.27.1 Dynasil Corporation of America Pipeline Products & Ongoing Clinical Trials Overview 53
5.28 Edan Instruments Inc Company Overview 54
5.28.1 Edan Instruments Inc Pipeline Products & Ongoing Clinical Trials Overview 54
5.29 Epinex Diagnostics Inc Company Overview 57
5.29.1 Epinex Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 57
5.30 ET Healthcare Inc Company Overview 58
5.30.1 ET Healthcare Inc Pipeline Products & Ongoing Clinical Trials Overview 58
5.31 Group K Diagnostics Company Overview 61
5.31.1 Group K Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 61
5.32 LeukoDx Ltd Company Overview 63
5.32.1 LeukoDx Ltd Pipeline Products & Ongoing Clinical Trials Overview 63
5.33 MML Ltd Company Overview 64
5.33.1 MML Ltd Pipeline Products & Ongoing Clinical Trials Overview 64
5.34 Nanomix Inc Company Overview 66
5.34.1 Nanomix Inc Pipeline Products & Ongoing Clinical Trials Overview 66
5.35 Novartis AG Company Overview 68
5.35.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 68
5.36 Ohmx Corp Company Overview 69
5.36.1 Ohmx Corp Pipeline Products & Ongoing Clinical Trials Overview 69
5.37 OPKO Health Inc Company Overview 73
5.37.1 OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 73
5.38 Prolight Diagnostics AB Company Overview 75
5.38.1 Prolight Diagnostics AB Pipeline Products & Ongoing Clinical Trials Overview 75
5.39 QLIDA Diagnostics Company Overview 76
5.39.1 QLIDA Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 76
5.40 QuickCheck Health Inc Company Overview 77
5.40.1 QuickCheck Health Inc Pipeline Products & Ongoing Clinical Trials Overview 77
5.41 Quidel Corp Company Overview 78
5.41.1 Quidel Corp Pipeline Products & Ongoing Clinical Trials Overview 78
5.42 Radiometer Medical ApS Company Overview 79
5.42.1 Radiometer Medical ApS Pipeline Products & Ongoing Clinical Trials Overview 79
5.43 Radisens Diagnostics Ltd Company Overview 80
5.43.1 Radisens Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 80
5.44 Resdin Technologies Inc. Company Overview 81
5.44.1 Resdin Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 81
5.45 Sandia National Laboratories Company Overview 82
5.45.1 Sandia National Laboratories Pipeline Products & Ongoing Clinical Trials Overview 82
5.46 Sarissa-Biomedical Ltd Company Overview 85
5.46.1 Sarissa-Biomedical Ltd Pipeline Products & Ongoing Clinical Trials Overview 85
5.47 Selfa, Inc. Company Overview 86
5.47.1 Selfa, Inc. Pipeline Products & Ongoing Clinical Trials Overview 86
5.48 SpinChip Diagnostics AS Company Overview 87
5.48.1 SpinChip Diagnostics AS Pipeline Products & Ongoing Clinical Trials Overview 87
5.49 Thermo Fisher Scientific Inc Company Overview 88
5.49.1 Thermo Fisher Scientific Inc Pipeline Products & Ongoing Clinical Trials Overview 88
5.50 ThreeFold Sensors (Inactive) Company Overview 89
5.50.1 ThreeFold Sensors (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 89
5.51 Trinity Biotech Plc Company Overview 90
5.51.1 Trinity Biotech Plc Pipeline Products & Ongoing Clinical Trials Overview 90
5.52 True Diagnostics Inc Company Overview 93
5.52.1 True Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 93
5.53 Universal Biosensors Inc Company Overview 94
5.53.1 Universal Biosensors Inc Pipeline Products & Ongoing Clinical Trials Overview 94
5.54 University of Vermont Company Overview 95
5.54.1 University of Vermont Pipeline Products & Ongoing Clinical Trials Overview 95
5.55 Upstream Medical Technologies Ltd Company Overview 96
5.55.1 Upstream Medical Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 96
5.56 XCellCure, LLC Company Overview 105
5.56.1 XCellCure, LLC Pipeline Products & Ongoing Clinical Trials Overview 105
6 Cardiac Markers Rapid Tests & Point of Care (POC) - Recent Developments 108
6.1 Oct 23, 2019: bioMerieux - Third-Quarter 2019 Business Review 108
6.2 Oct 22, 2019: bioMerieux - Third quarter 2019 business review 109
6.3 Oct 16, 2019: Trinity Biotech announces results for Q3, 2019 111
6.4 Sep 04, 2019: bioMerieux announces First-Half 2019 Results 112
6.5 Aug 20, 2019: Trinity Biotech announces results for Q2, 2019 115
6.6 May 07, 2019: Trinity Biotech announces results for Q1, 2019 117
6.7 Apr 24, 2019: bioMerieux: First-quarter 2019 business review 119
6.8 Mar 07, 2019: Trinity Biotech announces quarter 4 and fiscal year 2018 financial results 120
6.9 Feb 27, 2019: bioMerieux - 2018 Financial Results 122
6.10 Jan 25, 2019: Introducing DiaSys' new CEO Dr. Jan Gorka 126
6.11 Dec 07, 2018: Quidel comments on California court ruling 126
7 Appendix 127
7.1 Methodology 127
7.2 About GlobalData 130
7.3 Contact Us 130
7.4 Disclaimer 130

List of Tables
Table 1: Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 13
Table 2: Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Segment 14
Table 3: Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Territory 15
Table 4: Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path 16
Table 5: Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date 17
Table 6: Cardiac Markers Rapid Tests & Point of Care (POC) Companies - Pipeline Products by Stage of Development 18
Table 7: Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 21
Table 8: 1Drop Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 24
Table 9: One Drop Diagnostic Device - Cardiovascular Disease - Product Status 24
Table 10: One Drop Diagnostic Device - Cardiovascular Disease - Product Description 24
Table 11: Abbott Point of Care Inc Pipeline Products & Ongoing Clinical Trials Overview 25
Table 12: i-STAT TnI-Nx - Product Status 25
Table 13: i-STAT TnI-Nx - Product Description 25
Table 14: Accel Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 26
Table 15: pScreen BNP - Product Status 26
Table 16: pScreen BNP - Product Description 26
Table 17: Akers Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 28
Table 18: Diagnostic Test - Heart Attack - Product Status 28
Table 19: Diagnostic Test - Heart Attack - Product Description 28
Table 20: Akrivis Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 30
Table 21: Z-TECT - cTnI Assay - Product Status 30
Table 22: Z-TECT - cTnI Assay - Product Description 30
Table 23: Alfa Wassermann Inc Pipeline Products & Ongoing Clinical Trials Overview 31
Table 24: ACE Alera Clinical Chemistry System - hsCRP Assay - Product Status 31
Table 25: ACE Alera Clinical Chemistry System - hsCRP Assay - Product Description 31
Table 26: ACE Axcel Clinical Chemistry System - hsCRP Assay - Product Status 32
Table 27: ACE Axcel Clinical Chemistry System - hsCRP Assay - Product Description 32
Table 28: Angle Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 33
Table 29: Cardiac Troponin Biomarker Kit - Product Status 33
Table 30: Cardiac Troponin Biomarker Kit - Product Description 33
Table 31: Anteo Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 34
Table 32: AtomoRapid - Heart Attack - Product Status 34
Table 33: AtomoRapid - Heart Attack - Product Description 34
Table 34: Atonomics A/S Pipeline Products & Ongoing Clinical Trials Overview 36
Table 35: Premium Trace - B-type Natriuretic Peptide Assay - Product Status 36
Table 36: Premium Trace - B-type Natriuretic Peptide Assay - Product Description 36
Table 37: Trace - D-dimer Test - Product Status 37
Table 38: Trace - D-dimer Test - Product Description 37
Table 39: Axis-Shield Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 38
Table 40: Afinion hsCRP Assay - Product Status 38
Table 41: Afinion hsCRP Assay - Product Description 38
Table 42: BBB Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 39
Table 43: Mobile RDT Reader - Troponin-I Test - Product Status 39
Table 44: Mobile RDT Reader - Troponin-I Test - Product Description 39
Table 45: Bio-AMD Inc Pipeline Products & Ongoing Clinical Trials Overview 41
Table 46: Digital Strip Reader - Cardiac Marker Test - Product Status 41
Table 47: Digital Strip Reader - Cardiac Marker Test - Product Description 41
Table 48: Magnetic Immunoassay Detection System - Cardiac Myoglobin - Product Status 42
Table 49: Magnetic Immunoassay Detection System - Cardiac Myoglobin - Product Description 42
Table 50: Magnetic Immunoassay Detection System - Cardiac Troponin - Product Status 42
Table 51: Magnetic Immunoassay Detection System - Cardiac Troponin - Product Description 44
Table 52: Magnetic Immunoassay Detection System - CK MB - Product Status 44
Table 53: Magnetic Immunoassay Detection System - CK MB - Product Description 44
Table 54: BioMedomics Inc Pipeline Products & Ongoing Clinical Trials Overview 45
Table 55: Point of Care Test - Troponin - Product Status 45
Table 56: Point of Care Test - Troponin - Product Description 45
Table 57: BiOracle Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 46
Table 58: biO1042 Test - Product Status 46
Table 59: biO1042 Test - Product Description 46
Table 60: Biosensia Ltd Pipeline Products & Ongoing Clinical Trials Overview 47

List of Figures
Figure 1: Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 11
Figure 2: Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Segment 12
Figure 3: Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Territory 13
Figure 4: Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path 14
Figure 5: Cardiac Markers Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date 15

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Cardiac Markers Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027